IL163380A - Treating benign prostate hyperplasia with sarms - Google Patents

Treating benign prostate hyperplasia with sarms

Info

Publication number
IL163380A
IL163380A IL163380A IL16338004A IL163380A IL 163380 A IL163380 A IL 163380A IL 163380 A IL163380 A IL 163380A IL 16338004 A IL16338004 A IL 16338004A IL 163380 A IL163380 A IL 163380A
Authority
IL
Israel
Prior art keywords
type
subject
sarm
metabolite
isomer
Prior art date
Application number
IL163380A
Other languages
English (en)
Original Assignee
Univ Tennessee Res Foundation
Gtx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tennessee Res Foundation, Gtx Inc filed Critical Univ Tennessee Res Foundation
Publication of IL163380A publication Critical patent/IL163380A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Surgical Instruments (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
IL163380A 2002-02-07 2004-08-05 Treating benign prostate hyperplasia with sarms IL163380A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35430002P 2002-02-07 2002-02-07
US36299702P 2002-03-11 2002-03-11
PCT/US2003/003447 WO2003065992A2 (en) 2002-02-07 2003-02-06 Treating benign prostate hyperplasia with sarms

Publications (1)

Publication Number Publication Date
IL163380A true IL163380A (en) 2010-06-30

Family

ID=27737453

Family Applications (2)

Application Number Title Priority Date Filing Date
IL163380A IL163380A (en) 2002-02-07 2004-08-05 Treating benign prostate hyperplasia with sarms
IL202675A IL202675A (en) 2002-02-07 2009-12-10 Selective modulators of androgen receptor and their pharmacological compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL202675A IL202675A (en) 2002-02-07 2009-12-10 Selective modulators of androgen receptor and their pharmacological compositions

Country Status (20)

Country Link
US (2) US7776921B2 (enExample)
EP (1) EP1480634B1 (enExample)
JP (3) JP4677516B2 (enExample)
KR (2) KR101032661B1 (enExample)
CN (2) CN101732298B (enExample)
AT (1) ATE518537T1 (enExample)
AU (2) AU2003216174C1 (enExample)
BR (1) BRPI0307699A2 (enExample)
CA (2) CA2689080C (enExample)
CY (1) CY1111917T1 (enExample)
DK (1) DK1480634T3 (enExample)
EA (2) EA200901492A1 (enExample)
GE (1) GEP20074122B (enExample)
HR (2) HRP20040793A2 (enExample)
IL (2) IL163380A (enExample)
MX (1) MXPA04007639A (enExample)
PT (1) PT1480634E (enExample)
RS (1) RS69704A (enExample)
TW (2) TW200918043A (enExample)
WO (1) WO2003065992A2 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759520B2 (en) 1996-11-27 2010-07-20 University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
US7518013B2 (en) 2000-08-24 2009-04-14 University Of Tennessee Research Foundation Selective androgen receptor modulators
US7645898B2 (en) 2000-08-24 2010-01-12 University Of Tennessee Research Foundation Selective androgen receptor modulators and method of use thereof
US7622503B2 (en) 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US8445534B2 (en) 2000-08-24 2013-05-21 University Of Tennessee Research Foundation Treating androgen decline in aging male (ADAM)-associated conditions with SARMs
US7855229B2 (en) * 2000-08-24 2010-12-21 University Of Tennessee Research Foundation Treating wasting disorders with selective androgen receptor modulators
US7026500B2 (en) * 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
US7919647B2 (en) 2000-08-24 2011-04-05 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US20040260108A1 (en) * 2001-06-25 2004-12-23 Dalton James T. Metabolites of selective androgen receptor modulators and methods of use thereof
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US20070161608A1 (en) * 2001-12-06 2007-07-12 Dalton James T Selective androgen receptor modulators for treating muscle wasting
WO2004035739A2 (en) * 2002-10-16 2004-04-29 Gtx, Inc. Treating androgen decline in aging male (adam)-associated conditions with sarms
US20060276539A1 (en) * 2002-10-16 2006-12-07 Dalton James T Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS
US8309603B2 (en) 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
DE602004026583D1 (de) * 2003-06-27 2010-05-27 Orion Corp Als androgenrezeptormodulatoren geeignete propionamidderivate
FI20030958A0 (fi) * 2003-06-27 2003-06-27 Orion Corp Uusia yhdisteitä
EP1673376A4 (en) * 2003-10-14 2010-06-23 Gtx Inc TREATMENT OF BONE DISEASES WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS
EA009902B1 (ru) 2004-02-13 2008-04-28 УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл-Эл-Си Модуляторы рецепторов андрогенов
WO2005100305A1 (en) * 2004-04-13 2005-10-27 Warner-Lambert Company Llc Androgen modulators
WO2005102990A1 (en) 2004-04-22 2005-11-03 Warner-Lambert Company Llc Androgen modulators
US20110237664A1 (en) * 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
AU2005251781C1 (en) * 2004-06-07 2008-02-21 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
DK1753417T3 (da) * 2004-06-07 2012-07-23 Univ Tennessee Res Foundation Selektiv androgenreceptormodulator og medicinske anvendelser deraf
UA87854C2 (en) * 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
WO2006006065A1 (en) 2004-07-08 2006-01-19 Warner-Lambert Company Llc Androgen modulators
BRPI0513405A (pt) 2004-07-16 2008-05-06 Sunesis Pharmaceuticals Inc tienopirimidinas úteis como inibidores de aurora quinase
TW200724139A (en) 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
WO2007123682A2 (en) * 2006-04-03 2007-11-01 Medexis S.A. Detection of membrane androgen receptor (mar) agents
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
KR101264820B1 (ko) 2006-08-24 2013-05-22 유니버시티 오브 테네시 리서치 파운데이션 치환된 아실아닐리드 및 그의 사용 방법
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
JP2015509538A (ja) * 2012-03-07 2015-03-30 リガンド・ファーマシューティカルズ・インコーポレイテッド １つに統合された恒常性システムとしてのステロイドホルモン経路およびコレステロール経路
AU2013203784A1 (en) * 2012-04-06 2013-10-24 Kaushik J. Dave Needle assisted jet injection administration of testosterone compositions
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
JP6226978B2 (ja) 2012-07-13 2017-11-08 ジーティーエックス・インコーポレイテッド 選択的アンドロゲン受容体モジュレーター（ｓａｒｍ）によりアンドロゲン受容体（ａｒ）陽性乳癌を処置する方法
WO2015122858A1 (en) 2014-02-15 2015-08-20 Erdal Can Alkoçlar A composition containing synthetic components formed for suppressing ribonucleotide reductase
HUP1400294A2 (hu) 2014-06-13 2015-12-28 Skillpharm Kft Clopidogrel új alkalmazása
MX2017004819A (es) * 2014-10-16 2018-06-12 Gtx Inc Metodos de tratamiento de transtornos urológicos usando sarm.

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US644970A (en) * 1899-02-06 1900-03-06 Thomas Graham Donaldson Dental flask.
US935044A (en) * 1909-01-12 1909-09-28 Lenn G Mccorry Valve.
US935045A (en) * 1909-06-19 1909-09-28 Robert J Mckelvey Turn-table.
GB1360001A (en) 1971-06-16 1974-07-17 Scherico Ltd Pharmaceutical compositions comprising substituted anilides
US3875229A (en) 1972-11-24 1975-04-01 Schering Corp Substituted carboxanilides
JPS6044294B2 (ja) 1976-04-15 1985-10-02 帝国臓器製薬株式会社 アニリド誘導体
US4139638A (en) 1976-09-23 1979-02-13 Schering Corporation Methods for the treatment of hirsutism
EP0002309B1 (en) 1977-10-12 1982-12-01 Imperial Chemical Industries Plc Acylanilides, process for their manufacture and pharmaceutical and veterinary compositions containing them
US4191775A (en) 1977-12-15 1980-03-04 Imperial Chemical Industries Limited Amide derivatives
NZ197008A (en) 1980-05-22 1984-10-19 Ici Ltd Acylanilide derivatives and pharmaceutical compositions
JPS57171904A (en) 1981-04-15 1982-10-22 Mitsubishi Petrochem Co Ltd Tri- or tetra-substituted phenoxycarboxylic acid anilide type herbicide
EP0100172B1 (en) 1982-07-23 1987-08-12 Imperial Chemical Industries Plc Amide derivatives
GB8617653D0 (en) * 1986-07-18 1986-08-28 Ici Plc Amide derivatives
GB8617652D0 (en) 1986-07-18 1986-08-28 Ici Plc Acylanilide derivatives
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
EP0748220A4 (en) 1994-01-21 1997-09-10 Sepracor Inc METHOD AND COMPOSITIONS FOR TREATING ANDROGEN-DEPENDENT DISEASES USING OPTICALLY PURE R - (-) CASODEX
US5609849A (en) 1994-03-11 1997-03-11 The Trustees Of The University Of Pennsylvania Serotonin (5-HT1A) receptor ligands and imaging agents
US5656651A (en) 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
WO1998005962A1 (en) 1996-08-02 1998-02-12 Panvera Corporation A method for quantitating competitive binding of molecules to proteins utilizing fluorescence polarization
US20090264534A1 (en) * 1996-11-27 2009-10-22 Dalton James T Selective androgen receptor modulators
US6492554B2 (en) 2000-08-24 2002-12-10 The University Of Tennessee Research Corporation Selective androgen receptor modulators and methods of use thereof
US7205437B2 (en) * 1996-11-27 2007-04-17 University Of Tennessee Research Foundation Selective androgen receptor modulators
US6995284B2 (en) 2000-08-24 2006-02-07 The University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
US6071957A (en) 1996-11-27 2000-06-06 The University Of Tennessee Research Corporation Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
JPH10182457A (ja) * 1996-12-25 1998-07-07 Yuichi Hashimoto 抗アンドロゲン剤
US6160011A (en) 1997-05-30 2000-12-12 The University Of Tennessee Research Corporation Non-steroidal agonist compounds and their use in male hormone therapy
WO1998055153A1 (en) * 1997-06-04 1998-12-10 The University Of Tennessee Research Corporation Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging
JPH1135558A (ja) * 1997-07-18 1999-02-09 Zeria Pharmaceut Co Ltd ３−ベンゾイルインドール誘導体及びそれらを含有する医薬
GB9919778D0 (en) * 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
US6795776B1 (en) 1999-10-14 2004-09-21 Bristol-Myers Squibb Company Crystallographic structure of the androgen receptor ligand binding domain
IL149056A0 (en) 1999-10-19 2002-11-10 Nobex Corp Methods of asymmetrically synthesizing enantiomers of casodex, its derivatives and intermediates thereof
CA2389100A1 (en) 1999-10-27 2001-05-17 Nobex Corporation Resolution of intermediates in the synthesis of substantially pure bicalutamide
UA74826C2 (en) * 2000-05-17 2006-02-15 Ortho Mcneil Pharm Inc ?-carboline derivatives as phosphodiesterase inhibitors
AU2001288213B2 (en) 2000-06-28 2005-04-14 Bristol-Myers Squibb Company Selective androgen receptor modulators and methods for their identification, design and use
GB0016877D0 (en) * 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
US20030232792A1 (en) 2000-08-24 2003-12-18 Dalton James T. Selective androgen receptor modulators and methods of use thereof
US6998500B2 (en) 2000-08-24 2006-02-14 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
ES2321933T3 (es) 2000-08-24 2009-06-15 University Of Tennessee Research Foundation Moduladores selectivos del receptor de androgeno y metodos de uso de los mismos.
US6838484B2 (en) 2000-08-24 2005-01-04 University Of Tennessee Research Foundation Formulations comprising selective androgen receptor modulators
US20070161608A1 (en) * 2001-12-06 2007-07-12 Dalton James T Selective androgen receptor modulators for treating muscle wasting
PT1463497E (pt) 2001-12-06 2011-12-20 Gtx Inc Tratamento do desgaste muscular com moduladores selectivos do receptor de androgénios

Also Published As

Publication number Publication date
HK1068103A1 (en) 2005-04-22
AU2003216174B8 (en) 2009-01-15
JP2005522431A (ja) 2005-07-28
TWI374737B (en) 2012-10-21
JP2010209102A (ja) 2010-09-24
WO2003065992A3 (en) 2004-02-26
CA2689080A1 (en) 2003-08-14
DK1480634T3 (da) 2011-11-14
GEP20074122B (en) 2007-06-11
CN101732298B (zh) 2012-09-19
CA2689080C (en) 2011-07-05
BRPI0307699A2 (pt) 2015-06-16
JP4677516B2 (ja) 2011-04-27
CN1646115B (zh) 2010-06-09
CY1111917T1 (el) 2015-11-04
CA2475108A1 (en) 2003-08-14
EA013399B1 (ru) 2010-04-30
KR20040089606A (ko) 2004-10-21
WO2003065992A2 (en) 2003-08-14
US20040053897A1 (en) 2004-03-18
EA200901492A1 (ru) 2010-08-30
IL202675A (en) 2011-06-30
AU2003216174B2 (en) 2008-12-18
MXPA04007639A (es) 2005-07-13
EP1480634A4 (en) 2008-01-16
PT1480634E (pt) 2011-10-12
AU2003216174A1 (en) 2003-09-02
RS69704A (sr) 2006-12-15
EP1480634B1 (en) 2011-08-03
TW200307537A (en) 2003-12-16
JP2013144713A (ja) 2013-07-25
HRP20040793A2 (en) 2006-10-31
HRP20100067A2 (hr) 2010-04-30
CN101732298A (zh) 2010-06-16
KR101032661B1 (ko) 2011-05-06
US8088828B2 (en) 2012-01-03
ATE518537T1 (de) 2011-08-15
EP1480634A2 (en) 2004-12-01
AU2009201084A1 (en) 2009-04-09
EA200401043A1 (ru) 2005-06-30
AU2003216174C1 (en) 2010-01-28
KR20100112659A (ko) 2010-10-19
TW200918043A (en) 2009-05-01
US7776921B2 (en) 2010-08-17
CN1646115A (zh) 2005-07-27
US20100280107A1 (en) 2010-11-04

Similar Documents

Publication Publication Date Title
IL163380A (en) Treating benign prostate hyperplasia with sarms
WO2001044247A3 (en) Agents and methods for the treatment of proliferative diseases
WO2005000213A8 (en) Method for treating diseases using hsp90-inhibiting agents in combination with enzyme inhibitors
MXPA04002397A (es) Inhibidores de histona deacetilasa.
AP1498A (en) Inhibitors of impdh enzyme.
WO2004093826A3 (en) Compositions of cyclooxygenase-2 selective inhibitors and 5-ht1b/1d agonists for the treatment and prevention of migraine
WO2005023179A3 (en) Combination methods of treating cancer
WO2004108157A8 (en) Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
WO2003088958A3 (en) Combinations of cox-2 inhibitors and other agents for the treatment of parkinson’s disease
WO2003065988A3 (en) A combination for treating cold and cough
WO2004052236A3 (en) Methods and compositions for treatment of otitis media
WO2003048122A3 (en) Inhibitors of cytosolic phospholipase a2
WO2004064735A3 (en) Treatment of benign prostatic hyperplasia
WO2000007576A3 (en) INHIBITORS OF TYPE 3 3α-HYDROSTEROID DEHYDROGENASE
WO2003092606A3 (en) Cholinesterase inhibitors to prevent injuries caused by chemicals
WO2003094921A3 (de) Verwendung von hemmern der egfr-vermittelten signaltransduktion zur behandlung von gutartiger prostatahyperplasie (bph)/prostatahypertrophie
WO2022256723A3 (en) Tgf-beta inhibitors and therapeutic use thereof
WO2005016327A3 (en) Treatment of sleep disorders with cholinesterase inhibitors
WO2001056555A3 (en) Use of cox-2 inhibitors for the treatment of constipation
WO2003101380A3 (en) Amyotrophic lateral sclerosis treatment with cyclooxygenase-2 inhibitors
WO2001044235A3 (en) Agents and methods for the treatment of proliferative diseases
IL158762A0 (en) Prevention of addiction in pain management
WO2003094967A3 (en) New combination of reversible proton pump inhibitors and airway therapeutics for treating airway disorders
MX2007007051A (es) Nuevos derivados de tiofenpirimidiona sustituida como inhibidores de la 17??-hidroxiesteroide deshidrogenasa.
MXPA04005310A (es) Inhibidores de fosfolipasa a2 citosolica.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees